CorMedix Inc. announced the appointment of Paulo F. Costa to its Board of Directors. Paulo currently serves as Chairman of the Board of MacroGenics. In addition, he served as Chairman of Amylin Pharmaceuticals, until its sale to Bristol-Myers Squibb and AstraZeneca in a $7 billion transaction in 2012. Prior to his retirement, Paulo served in senior leadership roles at Novartis, including President and CEO of Novartis US Corporation from 2005 to 2008 and President and CEO of Novartis Pharmaceutica US and Head of Americas from 1999 to 2005. Prior to joining Novartis, Paulo spent 30 years at Johnson & Johnson including as President of Janssen Pharmaceutica Inc.